AIM News & Events

AIM ImmunoTech commenced its previously disclosed rights offering. Pursuant to the Rights Offering, the Company is distributing to all holders of record of the Company's common stock, par value $0.001 per share and to holders of certain options and warrants that have the right to participate in the Rights Offering, as of 5:00 p.m., Eastern Time, on February 10, at no charge, non-transferable subscription rights to purchase up to an aggregate of 12,000 units at a subscription price of $1,000 per whole Unit.

AIM ImmunoTech reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care. This is a follow-up Phase 2 to a 57-subject early access program, EAP, of Ampligen as a monotherapy in late-stage pancreatic cancer, where Ampligen was associated with median survival of 19.7 months, which is an extension of median overall survival of 8.6 months when compared to the standard of care. The EAP subjects also reported improved quality of life.